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Abstract
Background: Chemokine CXC ligand 13 (CXCL13) has been implicated in perivascular inflammation and pulmonary
vascular remodeling in patients with idiopathic pulmonary artery hypertension (IPAH). We wondered whether
CXCL13 may also play a role in chronic thromboembolic pulmonary hypertension (CTEPH) and whether serum
levels of CXCL13 might serve as biomarkers in these conditions.
Methods: Lung tissue from patients with IPAH or CTEPH was immunostained for CXCL13. Serum samples were
obtained from patients with IPAH (n = 42) or CTEPH (n = 50) and from healthy controls (n = 13). Serum CXCL13
concentrations were measured by enzyme-linked immunosorbent assay technology and were evaluated for
associations with markers of disease severity and survival.
Results: CXCL13 was expressed in pulmonary vascular lesions and lymphocytes of patients with IPAH and inoperable
CTEPH, respectively. Serum CXCL13 was elevated in patients compared to healthy controls [median, interquartile range,
83 (55,114) pg/ml versus 40 (28, 48) pg/ml; p < 0.001]. Serum CXCL13 showed only weak and inconsistent correlations
with markers of inflammation or disease severity. In both populations, patients with serum CXCL13 above the median
of the respective groups did not have a higher risk of death than patients with lower serum CXCL13.
Conclusions: CXCL13 was overexpressed in pulmonary vascular lesions of patients with IPAH and CTEPH, and increased
serum concentrations were found in patients with IPAH and CTEPH, suggesting a potential pathogenic role of CXCL13 in
both diseases. However, given the weak associations between serum CXCL13 and markers of disease severity and
outcome, CXCL13 is unlikely to become a promising biomarker in these patient populations.
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Background
Idiopathic pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension (CTEPH)
are diseases characterized by a progressive increase in pul-
monary vascular resistance due to an obliterative pulmonary
vasculopathy which eventually results in right heart failure
and death, if not effectively treated [1, 2].
The pathogenesis of pulmonary vascular remodeling in
both IPAH and CTEPH is not completely understood,
but an inflammatory component has been noted in both
conditions [3–7]. Perivascular accumulation of B-type
and T-type lymphocytes has been demonstrated in the
lungs of patients with PAH as well as CTEPH [6, 8], and
even pulmonary lymphoid neogenesis was demonstrated
in patients with IPAH [9].
Chemokine CXC ligand 13 (CXCL13), also known as C-
X-C motif chemokine 13, B-lymphocyte-chemoattractant
(BLC) or B-cell-attracting chemokine-1 (BAC-1) is a CXC
subtype member of the chemokine superfamily [10]. The
receptor of CXCL13, C-X-C chemokine receptor type 5
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(CXCR5), is expressed on mature B-cells and follicular T-
helper cells [10]. CXCL13 and CXCR5 are key players in
the trafficking of B-cells, and CXCL13 serum levels are in-
creased in various autoimmune disorders as well as in pa-
tients with idiopathic pulmonary fibrosis [11]. Perros et al.
have recently shown that CXCL13 mRNA is strongly
expressed and co-located with lymphoid neogenesis in
lung tissue from patients with IPAH [9].
The objectives of the present study were (i) to confirm
the findings by Perros et al. [9] in patients with IPAH,
(ii) to demonstrate whether increased CXCL13 activity
can also be found in lungs from patients with CTEPH
and (iii) to investigate whether serum levels of CXCL13




Patients diagnosed with IPAH or inoperable CTEPH be-
tween January 1st, 2007 and December 31st, 2014 were eli-
gible for this study. Follow-up ended April 15th, 2015. The
diagnoses of both conditions were made according to
standard criteria [12] and included ventilation/perfusion
scintigraphy and right heart catheterization in all patients.
For the assessment of CTEPH, pulmonary angiography was
mandatory. A multidisciplinary team of experts made the
decision about operability. Patients with post-capillary pul-
monary hypertension, connective tissue disease and signifi-
cant parenchymal lung disease were excluded from this
study.
Blood samples from healthy volunteers were collected as
controls. Written informed consent was provided from all
patients and controls and the Hannover Medical School
ethics committee (Ethikkommission der Medizinischen
Hochschule Hannover) approved this study.
Right heart catheterization
Right heart catheterizations were performed via a jugular
approach following a standardized protocol. The pressure
transducer was zeroed at the mid-thoracic level. Measure-
ments included right atrial pressure, mean pulmonary
arterial pressure (PAPm), pulmonary arterial wedge pres-
sure (PAWP) and mixed venous oxygen saturation (SvO2).
Cardiac output (CO) was measured by thermodilution
with the reported value being the average of at least three
Table 1 Characteristics of patients and controls at inclusion









Age (years) 59 ± 17 49 ± 17 68 ± 12 46 ± 16 <0.01 0.010
Female (%) 54 67 44 54 0.030 0.973
Body mass index (kg/m2) 27 ± 6 28 ± 7 26 ± 5 23 ± 3 0.259 0.009
NYHA II/III/IV (n) 0/10/76/6 0/7/33/2 0/3/43/4 n.a. n.a. n.a.
6 min walking distance (m) 330 ± 122 350 ± 115 314 ± 126 n.a 0.165 n.a.
Right atrial pressure (mmHg) 7 ± 5 8 ± 5 5 ± 4 n.a 0.004 n.a.
Mean pulmonary artery pressure (mmHg) 47 ± 14 53 ± 14 41 ± 10 n.a <0.01 n.a.
Pulmonary arterial wedge pressure (mmHg) 8 ± 3 8 ± 3 8 ± 3 10 0.638 n.a.
Cardiac output (L/min) 4.3 ± 1.2 4.3 ± 1.4 4.4 ± 1.2 n.a 0.733 n.a.
Cardiac index (L/min/m2) 2.3 ± 0.6 2.3 ± 0.7 2.3 ± 0.5 n.a 0.955 n.a.
Pulmonary vascular resistance (dyn · s · cm−5) 802 ± 416 970 ± 455 661 ± 321 n.a <0.01 n.a.
Mixed venous oxygen saturation (%) 63 ± 7 63 ± 8 63 ± 6 n.a 0.991 n.a.
CXCL13 (pg/ml) 120 ± 124 122 ± 127 118 ± 124 42 ± 15 0.858 0.026
CXCL13 (pg/ml) Median (IQR) 83 (55,114) 81 (64,113) 84 (51,120) 40 (28,48) 0.597*** <0.001***
CRP (mg/l) 9 ± 15 8 ± 10 10 ± 17 n.a 0.583 n.a.
S-Sodium (mmol/l) 140 ± 3 140 ± 3 140 ± 3 n.a 0.259 n.a.
NT-proBNP (ng/l) 2,530 ± 2,222 2,761 ± 2,165 2,333 ± 2,278 n.a 0.412 n.a.
NT-proBNP (ng/l) Median, IQR 1,929 (802–3,413) 1,995 (1,276-4,010) 1,747 (658–3,257) n.a 0.222*** n.a.
Bilirubin (μmol/l) 15 ± 9 17 ± 9 14 ± 9 n.a 0.069 n.a.
Uric acid (μmol/l) 411 ± 154 415 ± 142 407 ± 167 n.a 0.876 n.a.
Creatinine (μmol/l) 90 ± 24 85 ± 26 94 ± 22 n.a 0.076 n.a.
eGFR ml/min/1,73 m2 75 ± 26 83 ± 31 69 ± 18 n.a 0.008 n.a.
*IPAH vs. CTEPH, **IPAH and CTEPH combined versus controls
n.a. not available, ***Mann-Whitney U-test
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recordings with less than 10 % variation. PVR was calcu-
lated according to standard formula.
Measurements of circulating CXCL13 levels
Venous blood for quantification of circulating CXCL13
levels was obtained from patients with IPAH and
CTEPH at the time of right heart catheterization. The
blood samples were immediately placed on ice, centri-
fuged at 1000 g for 10 min and stored at −80 °C. Serum
concentrations of CXCL13 were quantified by the com-
mercially available Quantikine enzyme-linked immuno-
sorbent essay (ELISA) methodology according to the
manufacturer’s instructions (R&D Systems, Minneapolis,
MN, USA, Catalog Number DCX130). All samples were
measured in duplicates. Color intensity was measured by
a standard ELISA Reader (Tecan spectra mini, Crailsheim,
Germany). Quantikine kit standards were used for con-
struction of standard curves.
Immunohistochemical staining
Explanted lungs were available from three patients with
IPAH and one patient with CTEPH. Lung tissue from
three organ donors was used as control. Serially cut
slides of formalin-fixed and paraffin embedded lung tis-
sues were immunohistochemically stained for CXCL13
using polyclonal antibody (LS-C104337; LSBio, Seattle
WA, USA) following our established standard ABC
protocol [13].
Statistical analysis
Data are shown as mean ± standard deviation (SD). For
comparison of the study populations, Fisher’s exact test,
Chi-square test and two-sided paired t-test were used as
appropriate. Potential associations of CXCL13 with clin-
ical and hemodynamic variables were assessed with Pear-
son’s correlation analysis and two-sided testing for
significance. Kaplan-Meier estimates on survival were
made for patients with IPAH and CTEPH based on their
CXCL13 levels above or below the median of the respect-
ive groups. Comparisons were made by log-rank analysis.
P-values <0.05 were considered statistically significant.
Results
The study enrolled 92 patients (IPAH, n = 42; CTEPH,
n = 50) and 13 healthy controls. The demographics
and baseline characteristics are shown in Table 1.
Table 2 Correlations of serum CXCL13 with clinical, hemodynamic




Table 3 Correlations of serum CXCL13 with clinical, hemodynamic







Fig. 1 Box plot showing serum CXCL13 in healthy controls compared to patients with idiopathic pulmonary arterial hypertension (IPAH) and patients
with chronic thromboembolic pulmonary hypertension (CTEPH)
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 Fig. 2 (See legend on next page.)
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CXCL13 serum concentrations in patients with IPAH and
CTEPH
As shown in Table 1 and Fig. 1, serum CXCL13 was ele-
vated in the patient cohort compared to the control
group (120 ± 124 pg/ml versus 42 ± 15 pg/ml; p = 0.026).
There were no significant differences in CXCL13 levels
between IPAH and CTEPH patients (122 ± 127 pg/ml
versus 118 ± 124 pg/ml; p = 0.858).
Correlations between serum CXCL13 and markers of
disease severity
In the whole group (IPAH and CTEPH combined), there
were no significant correlations of serum CXCL13 with
clinical, laboratory and hemodynamic parameters (data
not shown). As shown in Table 2, patients with IPAH
showed a significant correlation between CXCL13 and
CRP; which was, however, not found in patients with
CTEPH. In the latter group, there were statistically sig-
nificant correlations between CXCL13 and right atrial
pressure, cardiac output, cardiac index and PVR,
respectively (Table 3). These correlations were relatively
weak and were not seen in patients with IPAH. Patients
with particular high serum CXCL13 (>200 pg/ml; Fig. 1)
did not differ from the rest of the cohort in terms of
age, sex or hemodynamics (data not shown).
Serum CXCL13 and survival
As shown in Fig. 2a and b, patients with higher serum
CXCL13 as defined by levels above the respective group
medians did not have a higher mortality risk compared to
their counterparts with lower serum CXCL13 (p = 0.786 for
the IPAH cohort and p = 0.330 for the CTEPH cohort).
CXCL13 expression in lungs from patients with IPAH and
CTEPH
Immunohistochemical CXCL13 staining of the explanted
lungs from the controls showed weak positivity in bronchial
epithelium but not in pulmonary vascular endothelial cells.
Perivascular lymphocytes were not visible (Fig. 3a).
Immunohistochemical CXCL13 staining of explanted
lungs from patients with IPAH (Fig. 3b) and CTEPH
(Fig. 3c) showed positivity in pulmonary vascular endo-
thelial cells, bronchial epithelium, lymphatic vessels and
perivascular lymphocytes.
Discussion
Our findings confirm a previous study from Perros et al.






Fig. 3 a. Immunostaining for CXCL13 in an explanted lung from an
organ donor showing weak positivity in bronchial epithelium
(double arrow heads a), but not in pulmonary vascular endothelial
cells (arrow heads a), [Original magnification, A × 100, B × 200].
b. Immunostaining for CXCL13 in an explanted lung from a patient
with idiopathic pulmonary hypertension showing positivity in pulmonary
vascular endothelial cells (arrow heads A), bronchial epithelium (double
arrow heads a) and perivascular lymphocytes (*a, *b) [Original
magnification, A × 100, B × 200]. c. Immunostaining for CXCL13 in
an explanted lung from a patient with chronic thromboembolic
pulmonary hypertension showing positivity in pulmonary vascular
endothelial cells (arrow heads a), bronchial epithelium (arrow heads b)
and peribronchial lymphocytes (*b) [Original magnification, × 200]
(See figure on previous page.)
Fig. 2 a Kaplan Meier Analysis showing probability of survival in patients with idiopathic pulmonary arterial hypertension according to serum CXCL13
above or below the median group value. The difference between both groups was not statistically significant (p= 0.786 by Log-Rank testing). b Kaplan Meier
Analysis showing probability of survival in patients with chronic thromboembolic pulmonary hypertension according to serum CXCL13 above
or below the median group value. The difference between both groups was not statistically significant (p = 0.330 by Log-Rank testing)
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vasculature of patients with IPAH. We extend these
findings by showing that CXCL13 was also expressed in
the pulmonary vasculature of a patient with CTEPH. In
addition, we found increased serum CXCL13 in both pa-
tient populations compared to healthy controls. How-
ever, serum CXCL13 did show only weak and
inconsistent correlations with markers of inflammation
and disease severity in patients with IPAH and CTEPH.
Furthermore, elevated serum CXCL13, i.e. CXCL13 con-
centrations above the median of the respective group,
were not associated with worse survival. This is in con-
trast to the findings of Vuga et al. in patients with idio-
pathic pulmonary fibrosis (IPF) [11].
Our findings support the notion that inflammation is in-
volved in the pathogenesis of IPAH and CTEPH. More
specifically, they support a previous study by Perros et al.
[9], which suggested that the lymphocytic inflammation of
pulmonary vessels seen in IPAH is at least partly mediated
by CXCL13. In addition, our data indicate that similar
mechanisms may play a role in CTEPH. The role of
CXCL13 and its receptor CXCR5 for lymphocyte migra-
tion was described in gene targeted mice more than a dec-
ade ago [14, 15], and was confirmed in different human
diseases with inflammatory components [11, 16, 17].
Although not formally proven, it is likely that the ele-
vated serum levels of CXCL13 found in patients with
IPAH and CTEPH result from a spillover of CXCL13
overexpressed in the lungs. We did not observe relevant
associations between serum CXCL13 and markers of
disease severity or mortality in both patient populations.
This does not exclude the possibility that serum
CXCL13 might reflect disease activity, but our study de-
sign did not allow us to explore this hypothesis.
Our study has several limitations including the retro-
spective design and the single center setting. Lung tissue
was available from only a few patients. We do not con-
sider this a major problem in IPAH as our data were
merely meant to confirm a previous study [9]. However,
lung tissue was available only from a single patient with
CTEPH as lung transplantation is performed rarely in
these patients. This finding awaits further confirmation
by others. In addition, we had no information on the
BMPR2 mutation status in our patient cohorts. The
sample sizes for serum CXCL13 analyses in patients with
IPAH and CTEPH were relatively small. Larger series
might have yielded statistically significant associations
with serum CXCL13 and markers of disease severity and
survival. However, it is unlikely that larger studies would
have resulted in a substantial change of our main
findings.
Conclusions
Our findings support the notion that CXCL13 might be
associated with pulmonary vascular remodeling in IPAH
and CTEPH, but it is unlikely that serum CXCL13 will
be a useful biomarker in these conditions.
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